• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to heterocyclic substances, in particular the preparation of (3aS, 6aE) -1- (1-phenylethyl) -dihydro-1H-furo (3,4-D) -imidazole-2.4 (3H, 3aH) -dions of the total -ly (I), (II) specified in the description @ where R 1 - (R or S-1-phenylethyl R 2 - H, non- or substituted alkoxy group benzyl, alkoxycarbonyl or alkoxyalkyl intermediates for the synthesis of vitamin H - [(+) - biotin]. The goal is to create new intermediates of the specified purpose. Synthesis is carried out by hydrogenation of compound f-ly (II) with the aid of hydrogen in the presence of a platinum, rhodium or ruthenium catalyst on carbon, alumina or calcium carbonate. Moreover, if R 4 is (S) -1-phenylethyl and R 2 is as defined above, then hydrogenation is carried out in the presence of palladium on aluminum oxide or calcium carbonate. New substances are obtained with a yield of up to 54% they provide valuable vitamins in an easy and affordable way. 1 tab.
    公开号:SU1600631A3
    申请号:SU874203838
    申请日:1987-12-15
    公开日:1990-10-15
    发明作者:Мкгэррити Джон；Тенуд Леандер
    申请人:Лонца Аг (Фирма)；
    IPC主号:
    专利说明:

    05 WITH
    The invention relates to a process for the preparation of new compounds that are intermediate in the synthesis of vitamin H - (+) - biotin.
    The purpose of the invention is the synthesis of new compounds that are intermediate for the synthesis of vitamin H, which makes it possible to synthesize this valuable product using a simpler and more accessible method
    available not only as a vitamin, but also as a treatment for dermatosis and as a growth-promoting feed additive in agriculture.
    Preparation of (3aS, 6aR) -l- (H) - (1-phenylstil) -dihydro-1H-furo (3, -d) - -imidazole-2.4 (3N, ZaH) -dione.
    A solution of 8.98 g (36.8 mmol) is introduced into a 250 ml autoclave.

    CM
     (1-Phenylethyl) -1 H-furo-3,4-d) Ti # - dazole-2, A (H, bN) dione in 90 ml of DMF and 0.90 g of Eh / Alg03 (5%) is added . The autoclave is then twice washed twice with hydrogen and filled with water to a pressure of 40 bar. The mixture is stirred for 10 hours, after which the catalyst is filtered off. The solvent is distilled under a pressure of 13.3 mbar, and the residue is recrystallized from 10 ml of ethyl acetate.
    In the form of a white crystalline product, (3aS, 6aR) -l- t (R) - (l 15 -phenylethyl) 3-dihydro-1H-furo {3,4- (i) - -imidazole-2.4 (3N ZaH-Dmon with a yield of 4.89 g (54%). M.p. 153-154 C.
    H-NMR analysis (CDCl 3, 300 MHz), 1.61 (d, J 7 Hz, 3N); 3.45. (dd, 20 J 10.5 and 1.4 Hz, 1H); 3.95 (dd. J 10.5 and 5 Hz, 1H); 4.21 (d, J 9.5 Hz, 1H); 4.57 (ddd, 5J, 9.5 and 1.4 Hz, 1H); 5.24 (w s, IH); 5.31 (q, J 7 Hz, 1H), 7.4 (m, 5H) .5
    MS analysis (E.I. 70 eV): m / e 246 (30%) M, 231 (45%), 161 (28%), 105 (100%).,
    IR anagtase (KBG), cm: 3388, 1771. (c), 1669 (c), 1422, 1255, 6999.30
    UV analysis (MeOH), D 372 nm, 119, 256 nm, 764.
    Calculated,%: C 63.1; H 5.7, N11.3.
    ((246.27) 35
    Nakd,%: C, 63.4; H 5.7; N11.4. i M: JVC J CHC133 / + 2P, 7 Preparation of (, 6aR) -l - (S) - (l-fe-ethyl)} -dihydro-1H-furo (3,4-d) -Q-imidazole- 2.4 (ЗН, ЗаН) -dione.
    A solution of 3.7 g of tl5.16 mmol) l-.RS) - - (1-phenylethyl) 1-1H-furo (3,4-e) -imidazol-2, 4 (3N , 6H) -dione in, 100 ml of acetic acid and 0.4 g of palladium on active carbon (57) are added. The autoclave is then washed twice with hydrogen and pressurized to 50 bar. The mixture is stirred.
    room temperature for 15h. The catalyst is then filtered. The solvent is then evaporated at a pressure of 20 mbar and the resulting residue is chromatographed on silica gel (eluent is ethyl acetate).
    As a result of the elution, 2.0 g (yield 54%) of the desired product is obtained. After recrystallization in
    ethanol get white needles, f 23-125 C.
     H-NMR analysis (CDCl1, 300 MHz), S: 1.65 (d, J 7.4 Hz, 3N), 4.08 (d, .J 8.6 Hz, 1H), 4.12 (m , W) D, 37 (dd, J 10.3 and 4.8 Hz, 1H), 48 (dd, J 10.2 and 1.3 Hz, W), 5.36 (q, J 7, Hz, 1H); 5.48 (s, 1 H). V
    MS analysis (E.I. 70 eV): m / e 246 30%) 231 (45%), 161 (28%), 105 100%),
      0.5 CHC / 3 + 6.7. Elution then obtained (3aR, 6AB) -isomer with a yield of 1.05 g (28%).
    Preparation of (3aS, 6aR) (R) - (1-Fe-yl-ethyl) -3-benzyl-dihydro-1H-furo (3,4-d) -imidazol-2.4 (3N, ZaH) -dione.
    48 ml of dimethoxyethane and 0; 39 g (16.2 mmol) of sodium hydride were introduced into a three-necked flask with an ECO flask equipped with a magnetic stirrer in an argon atmosphere and without moisture access. Then 3.24 g (13.2 mmol) of (3aS, 6aR) -1 - (R) - (1-phenylethyl) 1-dihydro-1H-furo (3,4-d) -imidazole-2 , 4 (ЗН, ЗаН) -dione. After 10 minutes of stirring, 2.76 g (16.2 mmol) of benzyl bromide was added and the suspension was stirred for 30 minutes. The reaction mass is then evaporated. The residue is dissolved in 25 ml of dichloromethane and 25 ml of water. The solution is separated in phases and the aqueous phase is washed with water three times with 15 MP each. The organic phases are collected, dried with 5 g of magnesium sulphate and evaporated. (3aS, 6aR) -l-1 (R) - (1-phenylethyl) 1-3-benzyl-dihydro-1H-fu (3,4-d) -imidazol-2, 4 (ZH, ZaH) -dion with the release of 3.56 g 80.5%. Tp 163-164 ,.
    H-NMR (CDClg, 300 MHz),: 58 (d, J 7 Hz, 3N); 3.38 (dd, J 10 and 3 Hz, 1H); 3.82 (dd, J 0 and 5 Hz, 1H), 3.89 (d, J 9 Hz, 1H) 4.32 (d; J 15 Hz, W), 4.44 (ddd, J 9; 5 and 3 Hz, lH) i 5.05 (d, J 15 Hz, 1H), 5.36 (KB, J 7-Hz, 1H), 7.30-7.41. (m, YUN).
    KS-a aliz (E.I. 70 eV): m / e 336 (26%) M% 321 (9%), 231 (22%), 187.. (16%), 174 (), 105 (56%), 91 (100%).
    Calculated,%: C 71.4; H 6.0; 8.3.
     (336.39)
    Found,% C 71., H, H 6.2, N8.3.
    o (0.5 CHCl9 / + 122.3.

    , Preparation of (3aS, 6aP.) - l- (G (E) - (Lphenylethyl) J -3- (4-methoxybenzyl) -benzyl dihydro-1H-furo (3,4-d) -imidazol-2, .4 (ЗН, ЗаН) -dione.
    "
    To a solution of 50.0 g (0.2 mol) (3aS 6aE)) - (1-phenylethyl) -dihydro-lH-phypo-Tz, 4-d) -imidazol-2.4 (3H, 3aH-dione and 39.8 g (0.25 mol) of 4-methoxybenzyl chloride in 500 ml of dried H, H-dimethylformamide in 10 portions, over a period of 2 hours at -10 ° C, 9.75 g (0, 22 mol of sodium hydride (55% in liquid paraffin) under argon atmosphere. After that, stir the resulting reaction mixture for 2 hours at and then at room temperature for another 2 hours. Add 8 ml of acetic acid. Evaporate the mixture to dryness Dissolve the residue in 00 ml of water and 200 ml of dichloromethane. - phase by phase, after which the resulting aqueous phase is extracted twice with 100 ml of dichloromethane, and the organic phases are dried with magnesium sulfate and concentrated. After stirring the concentrated product in ethanol at refluxing temperature, cooling and filtration, 53.5 g (72%) of the final product are obtained in the form of white needles. TtTR, U6, 4 C.
    H-NMR analysis (CDCl 3, 300 MHz), s O: 1.58 (d, J 7 Hz, 3N); 3.37 (dd, j 10 and 3 Hz, 3N); 3.82 (s, 3N)} 3.82 (dd, J 10 and 5.5 Hz, 1H); 3.88 (D, J 8.5 Hz, IH) - 4.25 (d, J 14.5 Hz, 1H); 4.34 (ddd, J 8.5 and 5.5 Hz, 3N); 4.97 (d, J 14.5 Hz, IH); 5.34 (KB, J = 7 Hz, IH); 6.88 (d, J 8.5 Hz, 2H); 7.32-7.28 (m, 7H).
    t 00
      1 CHCIs / - | -104.7.
    Preparation of (3aS, 6aR) - (K) - (1-phenylethyl) -3-tert-butoxycarbonyl- -dihydro-1H-furo (3,4-d) -imidazol--2,4 (ЗН, ЗаН ) -dione.
    To a solution of 20.0 g (81 mmol) of (3aS, 6aR) - (E) - (, 1-phenylethyl) -dihydro-1H-furo (3,4-a) -imidazole-2.4 (3N, HOH) - -dione and 21.3 g (97 mol) of di-tert-butyl dicarbonate in 200 ml of dried M, I-dimethylformamide in 10 portions are added over 2 hours at -10 ° C under argon atmosphere, 83 g (88 mmol) of sodium hydride (55% in liquid paraffin). The reaction mass is stirred for 2 h at 5 s and
    1600631
    five

    u 15 20
    25
    2 more hours at room temperature. Then 1 ml of acetic acid is added to the mass, after which the mass is evaporated to dryness. The residue obtained is dissolved in 50 MP of water and 100 ml of dichloromethia, separated in phases and the aqueous phase is extracted with dichloromethane twice 100 ml. The organic phases are dried with magnesium sulfate and concentrated.
    After stirring in ethanol at reflux temperature, cooling and filtration, 25.8 g (92%) of the indicated product are obtained in the form of white needles. Mp 177.4-178;
    MHz)
    7.5 Hz
    ZN) 5 3.5 (/ -, J P Hz, 1H); 3.97 (dd, j 11 and 5 Hz, 1H); 4.50 (dd, J 8 and 5 Hz, 1H); 4.90 (d, J 8 Hz, 1H); 5.39 (q, J 7.5 Hz, 1H); 7.3-7.4 (m, 5H). ; / l | / C - 1 CHC1e / + 55.8 “.
    i pl I //, 4-17b ,.
     n-NMR spectrum (CDC13, 300 (1.59 (s, 9H), 1.63 (d, J
    - y 15 20 35
    40
    P
    Preparation of OaZ, 6aR) - (R) - (1-phenyl-ethyl)} -3-methoxymethyldihydro-1H-furo- (3,4-a) -imidazole-2.4 (3N, ZAH) -dione.
    To a solution of 19 g (77 mmol) (3aS,
    30 6aE) -CN) - (1-phenylethyl) -dihydro-1H- -phy- (3,4-d) -imidazol-2.4 (3H, 3H) -dione and 9.42 g (120 mmol) of chloromethyl methyl ether in 200 ml of N, N-dimethylformamide, 10 ml portion, for 4 hours, 4.0 g (93 mmol) of sodium hydride (55% in liquid paraffin) was added under argon atmosphere. The reaction mixture is then stirred for 2 hours at and 2 hours at room temperature, after which 2 ml of acetic acid are added. The mixture was evaporated to dryness, and the residue was dissolved in 50 ml of water and 100 MP of dichloromethane. After separation of the 45 solution in phases, the aqueous phase is extracted with dichloromethane twice in 100 MP each. The organic phases are dried with magnesium sulfate and concentrated.
    After chromatography of the oily residue with silica gel (500 ml of a mixture of dichloromethane and acetic acid methyl ester) and concentration of the fractions, 4.0 g (18%) of the indicated product are obtained in the form of a white powder. 5 TP, 96-98 ° C.
    H-NMR analysis (CDCT ,, 300 MHz), o: 1.61 (d, J 7.5 Hz, 3N); 3.36 (s, 3N); 3.41 (dd, J 10 and 3 Hz, IH); 3.89 (dd, J 10 and 6 Hz, 1H),
    4.36 (. J 9 GE. IH). 4.52 (tac; „J 9, 6 at 3 Hz, R), 4.37 (d, J - ii Hz, 1H); 4.57 (d, J 11 Hz, 1H) V 5.34 (KB, J 7.5 Hz, 1H), 7.35-7.4 (m „5H)
    , Preparation of (3aS j6aR) -l-.№) .- (bphenylethyl) 2 3 benzyl-igidro-1H-thiyo- (3,4-d) -imidazole-2.4 (ZN, ZaH) -dione. In a 25 mi flask equipped with a magnetic stirrer and an Allyn condenser, a solution of 2.03 g (6.03 mmol) (3aS, 6aR) -l- (10- (1-phenylethyl) 3 3-benzyl-di) is introduced .-tsdro-1 H-furo- (3,4-d) -imidazole-2.4 (3N, ZAH) -dione in 2 ml of dimethylacetamide. The solution is heated to and 0.81 g (7.14 mmol) of potassium thioacetate is added. 45 minutes after the reaction mixture is allowed to cool and it is treated with 40 ml of toluene and 40 MP of water. After phase separation, the toluene phase is washed with 20 ml of water each time, and the collected 4 water basics with toluene three times with 30 ml each. The toluene phases are collected, precipitated and concentrated. The solid brown vegetation thus obtained is washed with 5 ml of diethyl ether. Then the beige product is filtered off - (3aSj6aR) - -1-. (K) - (1-phenylethyl) 1 -3-benzyl-D14-hydro-1H-thiano- (3, 4-e) -imidazrl-2 ,four,
    (ZN, SaN) -dion and dry it. Yield: 1, 8.2 g 85% ,, T ,, 144-145 C. H-NMR analysis (CDCIg ,, 300 MHz),
    S: 1.67 (d, J = 7 Hz / 3N); 2.71
    (dd, J 12.5 and 2.5 Hz, 1H); 3.03. (dd, J 12.5 and 5 Hz, W); 3.81, (d,
    J 8 Hz, 1H); 4.34 (d, J 15 Hz,.
    1H); 4.40 (ddd, J 8; 5 and 2.5 Hz,
    W); 5.04 (d, j 15 Hz, 1H), 5.41
    (KB, J 7 Hz, W); 7.30-7.50 (m,
    1 OH).
    MS analysis (E, 1. 70 eV): m / e 352 324 (30%), 278 (35%), 174
    (80%), 146 (30%), 105 (70%), 91
    (100%) Calculated,%: C 68, -2; H5.7; N7.9; S 9.1
    iCgpHto zOiS (352, .46).
    Found,%: C 67.9; H, 5.9; N 8.0; 88,
     - 0.5 CHC / 3 + 128.5,
    Preparation of (Za5,6aP,.) - hexahydro-1- (K.) (1Pe1Ilethyl) 1--2 Oxo-3-benzyl Tieno- (3,4-d) -imide, azol-4-ylidendenone acid ,
    (1M
    B. A 25 ml round bottom flask was introduced with 159.8 mg (3.66 mmol) of sodium hydride and. 1, 7, ml of DMS. Then heat the resulting slurry with
    ten
    15
    )
    m 20 t-
    ,
    .
    one .
    one.
    - l-
    e
    6006318
    by shivin in argon before. Stirring is continued for 40 minutes until the evolution of hydrogen ceases. Then the solution is cooled to room temperature and a solution of 801.5 mg (1.8 mmol) of (4-carboxybutyl) -triphenylphosphonium bromide in 1 ml of DMS is added. The resulting dark red reaction mixture is stirred for 15 minutes, then it is added dropwise to a solution of 271 mg (0.77 mmol) (3aS, 6aR) -1-gR) - (1-phenylethyl) 3-3-ben - Zil-dihydro 1H-thieno- (3,4-d) -kmidol-2.4 (3N, ZaH) -dione in 2 ml of DOS and 0.2 ml of toluene. The reaction mass is stirred for 2 h at room temperature. Then, 1 g of ice, 1 t-in of hydrochloric acid and another 9 g of ice are added. After 5 minutes, 5 ml of water, 10 MP of benzene and 5 ml of ethyl acetate were added. The resulting mixture was stirred at 60 ° C for 1 h. Then the separation was carried out in 25 phases. The brown organic phase is dried with 5 g of magnesium sulphate and separated by 4 preparative thin-layer silica gel plates (1 mm) 5 eluting with ethyl acetate.
    The resulting product, (3aS, 6aR) - -hexahydro -) - (1 -phenyl-ethyl) 1 -2 -2oxo-3-benzylthieno (3,4-d) -imidazole 4-ylidenepentanoic acid is a colorless oil. The output of 38.2 mg (12%),
     H-Ya number analysis (CDClg, 300 MHz), (5: 1.58 (d, J 7 c, 3N); 1.59 (KB, J 7 Hz, 2H); 1, 98 (m, 2H) , 2.22 (t, J 7.5 Hz, 2H), -2.29 (dd, J 11.5 and 4 Hz, 1H); 2.41 (dd, J P, 5 and 5, Hz, W ); 3.97, (d, J 15 Hz, IB); 4.18 (m, 2H); 4.84 (d, J 15 Hz, 1H); 5.30 (KB, J 7 Hz, 1H) ; 5.31 (t, J = 7 Hz, H); 7.10-7.40 (m, YUN).
    MS analysis (E.I. 70 eV): w / e 436 (55%) M 331 (55%), 252 (32%), 237 (60%), 120 (40%), 106 (100%).
    Preparation of (3aS, 6aI) -hexahydro-1- - (R) - (l-phenylethyl) -2-oxo-3-benzylthieno (3,4-d) and dazol-4-ylidepentanoic acid i
    0.802 g (33 mmol) of magnesium fluxes is placed in 5 mp THF. Over a period of 1 hour, 2.37 g (11 mmol) of dibromobut per 30 ml of THF are added to the chips. The reaction mass will withstand more than 2 hours at a temperature of reflux. Then 2.55 g (22 mmol) is added to it.
    thirty
    35
    40
    45
    50
    55
    tetramethylstilenediamine and maintain the mass for another 1 h at reflux temperature. 3.52 g (10 mmol) of (3aS, 6aR) -l- (R) - (1-phenylethyl) 7-3-benzyl-dihydr0-1H- -tyenoSZ was added to the dose over a period of 20 min. 4-d) -imidazole-2,4- (3N, ZaR) - -one in 50 MP THF. The reaction mass is stirred for 2 h at room temperature and cooled to, during the course of f / 1 "v". - / ABOUT
    -L1.S.PS
    1 h at about ° C and 1 h at room
    niya
    Coal gas is introduced into the mass.
    160
    The reaction mass is poured onto 400 m) of an aqueous solution of sulfuric acid and extracted several times with toluene. To the toluene phase, 0.8 g of concentrated sulfuric acid is added, washed with water and concentrated on a rotary evaporator. 400 ml of j 10% potassium carbonate solution are added to the resulting residue and extracted with ethyl acetate. The organic phase is washed again. 10% potassium carbonate solution. The collected aqueous phases with water sulfur
    gpgzt - - -.
    thirty
    ice and 1.5 MP of concentrated hydrochloric acid, then extracted with ethyl acetate. The collected organic phases are washed with water and saturated saline solution, dried with sulphate, magnesium and concentrated.
    The residue is dissolved in 170 ml of toluene and 50 mg of p-toluenesulfonic acid is added to the solution. The mass is heated to reflux and the reaction water is distilled off using a water separator. The remaining toluene solution is concentrated and the resulting oil is chromatographed on silica gel, eluting with a mixture of ethyl acetate and toluene.
    Get I, 22 g (28%) of the specified product in the form of a yellowish oil.
    Preparation of (3aS, 6aP.) - hexahydro - - - CR; - (1-phenylethyl / -2-oxo-3-benzine thieno- (3,4-d) -imidazol-4-yliden-pentane acid).
    8.6 g of magnesium shavings are placed in 75 MP THF. B. For 15 minutes, a mixture of 3.2 g of 1,2-dibromoethane and 2.5 g of I, 4-dichlorobutane in 35 ml of THF is added to this mixture at such a rate that the mixture does not exceed 30-35 ° C. Then another 20.5 g of 1,4-dichlorobutane is added over 30 minutes. 75 MP THF. The reaction mass is maintained at this temperature for 3 hours, after which 9 g of tetramethylethylenediamine and 100 ml of THF are added to it. The reaction solution is then cooled to (-40) - (- 45) C, after which a solution of 30 g (3: 5,6aP.) - 1 - /: (10- (1-phenylethyl)) is added to it over 20 minutes. -Z-benzyl-hydroxy-1H-thieno- - (3,4-a) -imidazol-2.4 (2H, ZAH) -one in 180 ml of THF. At this temperature, stir the mass for 1 h and then carbon dioxide is introduced within 30 minutes.
    then they are repeatedly extracted vinegar. by ether. Dry the organic phase with magnesium sulfate and concentrate it. After adding hexane, the product precipitates and is filtered off and dried.
    Obtain 32.5 g (89.3%) of the specified product in the form of a white powder concentration (according to TLC), 0-102 ,.
      With methanol / + 253 ,.
    35
    40
    45
    50
    Preparation of (3aS, 6aR) -hexahydro-1- - L (R) (i-phenylethyl) -2-oxo-3-benzyl-pheno- (3,4-d) -imidazol-4-yl-pentaic 1SH slots.
    a solution of 78.6 mg (Za8.6aE) - hexahydro -1 -1 (K) - (- phenylethyl) 2-2-oxo-3-benzylthieno- (3.4- d) -imidazole-4-ylidene-pentane acid in 5 ml of isopropanol and add 39 mg of palladium-carbon (5). The autoclave is washed twice with hydrogen and the mass is stirred over 50 bar hydrogen pressure at 50 ° C for 24 hours. Then the catalyst is filtered off and the solvent is evaporated. As a product, (Za5, -6aH) -hexahydro-1-1 (K) - (1-phenylethyl) -2-oxo-3-benzylthieno (3,4-a) -imidazol-4-yl is obtained. pentanoic acid as a colorless oil with a yield of 56.1 mg (72%).
     H-NMR analysis (ASCS, 300 MHz), U 1.57 (m, 6H); 1.61 (d, J 7Hz, -ZH); 2.13 (m, 1H) - 2.33 (m, 2H); 3.03 (m, H); 3.90 (dd, J 10 and 5 Hz, 1H) 3.94 (d, J 15 Hz, 1H); 4.22, (m, 1H); 5.06 (d, J 15 Gp, 1H); 5.28 (KB, J = 7 Hz, IK); 7.20-7.40 (m, YUN).
    MS analysis (EI 70 eV): m / e 48 (13%), 423 (6%), 333 (16%), 187 (30%), 174 (15%), 105 (63%), 91 ( 100%). Getting a - biotin.


    0631.0
    The reaction mass is poured onto 400 m) of an aqueous solution of sulfuric acid and extracted several times with toluene. To the toluene phase, 0.8 g of concentrated sulfuric acid is added, washed with water and concentrated using a rotary evaporator. 400 ml jj of a 10% potassium carbonate solution are added to the residue obtained and extracted with ethyl acetate. The organic phase is washed again. 10% potassium carbonate solution. The collected aqueous phases with water sulfur
    .
    thirty
    m,
    about 25

    then they are repeatedly extracted vinegar. by ether. Dry the organic phase with magnesium sulfate and concentrate it. After adding hexane, the product precipitates and is filtered off and dried.
    Obtain 32.5 g (89.3%) of the specified product in the form of a white powder concentration (according to TLC), 0-102 ,.
      With methanol / + 253 ,.
    35
    40
    45
    0
    Preparation of (3aS, 6aR) -hexahydro-1- - L (R) (i-phenylethyl) -2-oxo-3-benzyl-pheno- (3,4-d) -imidazol-4-yl-pentaic 1SH slots.
    a solution of 78.6 mg (Za8.6aE) - hexahydro -1 -1 (K) - (- phenylethyl) 2-2-oxo-3-benzylthieno- (3.4- d) -imidazole-4-ylidene-pentane acid in 5 ml of isopropanol and add 39 mg of palladium-carbon (5). The autoclave is washed twice with hydrogen and the mass is stirred over 50 bar hydrogen pressure at 50 ° C for 24 hours. Then the catalyst is filtered off and the solvent is evaporated. As a product, (Za5, -6aH) -hexahydro-1-1 (K) - (1-phenylethyl) -2-oxo-3-benzylthieno (3,4-a) -imidazol-4-yl is obtained. pentanoic acid as a colorless oil with a yield of 56.1 mg (72%).
     H-NMR analysis (ASCS, 300 MHz), U 1.57 (m, 6H); 1.61 (d, J 7Hz, -ZH); 2.13 (m, 1H) - 2.33 (m, 2H); 3.03 (m, H); 3.90 (dd, J 10 and 5 Hz, 1H) 3.94 (d, J 15 Hz, 1H); 4.22, (m, 1H); 5.06 (d, J 15 Gp, 1H); 5.28 (KB, J = 7 Hz, IK); 7.20-7.40 (m, YUN).
    MS analysis (EI 70 eV): m / e 48 (13%), 423 (6%), 333 (16%), 187 (30%), 174 (15%), 105 (63%), 91 ( 100%). Getting a - biotin.
    n
    in a 25 ml round-bottomed flask, heat a solution of 100 mg. IL of pentanoic acid in A ml: 48% hydrobromic acid for 3 hours at 400 mbar under vacuum. After cooling the reaction mass, it is extracted with 5 ml of toluene. The aqueous phase is evaporated in vacuo. 10 ml of chloroform at. Concentrate
    :
    de R - K „(, R) - or (S) 1-phenylethyl, hydrogen, substituted by lower alkoxy group or not substituted benzyl, alkoxy26
    karbo l and h dinen
    About RlNrN Ri
    where Rt is (R) -l-phenylethyl;
    thirty
    mini or calcium carbonate or, if R (5) -1-phenylethyl, RU has the indicated values, is hydrogenated with hydrogen in the presence of a palladium catalyst on carbon, alumina or a cargo catalyst on carbon, alumina calcium carbonate.
    Ko has the indicated values, is hydrogenated with hydrogen in the presence of platinum, rhodium or ruthenium

    Fill the aqueous phase to 10 ml and cool. 40 mg of d - (+) - biotin are obtained in the form of beige-colored crystals (yield 72%). Tfin 227-229 p.
    0
      0.1 n. Kaon / + 84.5.
    Data on the receipt of the proposed compounds are summarized in table. invention formula
    The method of obtaining t3aS, 6aR) -l - (. L -phenyl ethyl) -dihydro-lH-phypo- (3,4-d) - -imidazole-2.4 (3N, ZA) -DIO General formula
    26
    carbonyl or alkoxyalkyl, about t - l and h a and HZ and with the fact that the compound of the general formula
    ABOUT
    mini R zann pr pron bon
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining (3,8,6aE) -1 - (. 1-phenylethyl) -dihydro-1H-furo (3,4-ά) -imidazol-2.4 (WE, ZeH) -dione general formula
    ten
    about .
    Ρ ,, Ν ^ ΝΠι
    H-M- "
    V 0
    2δ
    where E <'E „
    (K) - or (3) -1-phenylethyl, hydrogen, substituted by a lower alkoxy group, or unsubstituted benzyl, alkoxycarbonyl, or alkoxyalkyl, due to the fact that the compound of the general formula
    one
    where E <- (E) -1-phenylethyl;
    K. £ has the indicated values, hydrogenates with hydrogen in the presence of a platinum, rhodium or ruthenium catalyst on coal, aluminum oxide
    minium or calcium carbonate or, if E "- (5) -] - phenylethyl, H." 2 has the indicated values, is hydrogenated with hydrogen in the presence of a palladium catalyst on carbon, alumina or calcium carbonate.
    Exampleto " Catalyst Amount of catalyst, Ζ Exit, 2 M.p. ° С one K-Phenylethyl Hydrogen EB / A1. e About five 54 153-154 2 5-phenylethyl Hydrogen P <5 / C five 54 123-125 3 5-phenylethyl Benzyl P4 / A1 X! C 9five 51 163-164,5 four 5-phenylethnl Hydrogen Ρό / CaCOe ' 7 48 122-124 five K-Phenylethyl Methoxymethyl КЬ / С five 51 96-98 6 K-Phenylethyl 4-methoxybeneyl RS / S five 50 146.1-146.4 7 K-Phenylethyl Hydrogen Κυ / ΑΙ ^ Ο} five · 46 154 eight K-Feiietil Hydrogen КЬ / <РЬ) $ Р / Э С1 42 153-153,5 9 . K-Feiietil tert-Butoxy- КЬ / А1 Й О Эfive 50 177.4-178.1 carbonyl ten K-Phenylethyl Hydrogen H1 / A1aO lten 54 153-154 eleven 8-phenylethnl Hydrogen D / s one 46 124-125
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1600631A3|1990-10-15|Method of producing|-1-|-dihydro-1n-|-imidazol-2,4|-dions
    Rebek Jr et al.1984|Synthesis of ergot alkaloids from tryptophan
    CN102574864B|2015-04-29|Fused aminodihydropyrimidone derivatives
    Anderson et al.1977|Synthesis and antileukemic activity of 5-substituted 2, 3-dihydro-6, 7-bis |-1H-pyrrolizine diesters
    AU627255B2|1992-08-20|Intermediates in synthesis of optically active aryloxypropanolamines &amp; arylethanolamines
    Tanino et al.2004|Total syntheses of |-vallesamidine and related Aspidosperma and Hunteria type indole alkaloids from the common intermediate
    EP2393779A2|2011-12-14|Process for the synthesis of cleistanthin
    US4851540A|1989-07-25|Process for the production of biotin precursors
    Danieli et al.1994|Aspidosperma alkaloids via cyclization of secodine intermediate: Synthesis of |-3-oxovincadifformine ethyl ester.
    Wenkert et al.1988|A formal total synthesis of kopsinine
    Kuehne et al.1987|Three routes to the critical C16'-C14'parf relative stereochemistry of vinblastine. Syntheses of 20'-desethyl-20'-deoxyvinblastine, and 20'-desethyl-20'-deoxyvincovaline
    Toda et al.1974|The alkaloids from the fruits of the plant Daphniphyllaceae
    CA1077948A|1980-05-20|1,-5 disubstituted-2-pyrrolidones and processes for their production
    Cao et al.2015|Cascade N-Alkylation/Hemiacetalization for Facile Construction of the Spiroketal Skeleton of Acortatarin Alkaloids with Therapeutic Potentiality in Diabetic Nephropathy
    Loreto et al.2007|Novel Spiroheterocycles by Aziridination of α‐Methylene‐γ‐and‐δ‐lactams
    Bastida et al.1992|Narcissus alkaloids, XIV.|-8-O-Acetylhomolycorine and vasconine, two novel alkaloids from Narcissus vasconicus
    Varea et al.1995|Asymmetric synthesis. XXXV1. Synthesis of 2-methyl 5-substituted substituted piperidines from chiral non-racemic lactams
    Wuts et al.1988|Synthesis of the cannabisativine skeleton via an intramolecular allylsilane-nitrone cycloaddition
    Ma et al.2000|Synthesis of |-2-|-glycine via the Stereochemically Controlled Cyclopropanation of |-Glyceraldehyde Acetonide-Derived Enones
    US4087438A|1978-05-02|Thieno[3,4-d]furoxan and process for its preparation
    US5162540A|1992-11-10|Process for the production of | biotin
    US4267330A|1981-05-12|Process for the synthesis of vincadifformine and related derivatives
    Kume et al.1987|Regioselective addition of organocuprates to 2-siloxypyrylium salt: Facile synthesis of substituted 2-siloxy-4H-pyrans and their reactions with electrophiles
    Savelli et al.1996|Synthesis of 1H‐pyrazino [1, 2‐a] pyrido [2, 3‐e] pyrazine and 2H‐Pyrano [2, 3‐b] pyrido [2, 3‐e] pyrazine Derivatives
    Kumar et al.1986|Synthesis of dihydrodiols and diol epoxides of dibenz [a, h] acridine
    同族专利:
    公开号 | 公开日
    NO875279L|1988-06-20|
    US4876350A|1989-10-24|
    IE873307L|1988-06-18|
    IL84770A|1993-05-13|
    IE60518B1|1994-07-27|
    FI90423C|1994-02-10|
    IL84770D0|1988-05-31|
    FI875371A0|1987-12-07|
    JPS63165387A|1988-07-08|
    HUT47290A|1989-02-28|
    NO166941B|1991-06-10|
    DK638287A|1988-06-19|
    NO166941C|1991-09-18|
    HU199475B|1990-02-28|
    US5117003A|1992-05-26|
    EP0273270A1|1988-07-06|
    EP0273270B1|1992-04-08|
    AT74606T|1992-04-15|
    PT86401A|1988-01-01|
    CA1322757C|1993-10-05|
    DK638287D0|1987-12-04|
    JP2560360B2|1996-12-04|
    PT86401B|1990-11-20|
    YU46432B|1993-10-20|
    CH670644A5|1989-06-30|
    ES2032428T3|1993-02-16|
    DD264920A5|1989-02-15|
    DE3778135D1|1992-05-14|
    NO875279D0|1987-12-17|
    YU229487A|1988-10-31|
    JPH08319290A|1996-12-03|
    FI90423B|1993-10-29|
    FI875371A|1988-06-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2784191A|1957-03-05|Process for the production of lactams |
    DE154225C|
    US2489235A|1947-07-24|1949-11-22|Hoffmann La Roche|Synthesis of biotin|
    US2535010A|1948-10-02|1950-12-19|Rohm & Haas|Transetherification of beta-ethersubstituted esters|
    DE850007C|1950-12-22|1952-09-22|Basf Ag|Process for the preparation of N-aryl-ª ‡ -pyrrolidones|
    JPS463580Y1|1967-06-13|1971-02-06|
    BE759512A|1969-11-29|1971-05-27|Hoffmann La Roche|LACTONE|
    DD111577A5|1972-06-22|1975-02-20|
    JPS5315074B2|1973-06-14|1978-05-22|
    JPS5067627A|1973-10-17|1975-06-06|
    IT1045043B|1975-08-13|1980-04-21|Isf Spa|PYROLIDINE DERIVATIVES|
    IT1075564B|1977-02-11|1985-04-22|Isf Spa|PROCEDURE FOR THE PREPARATION OF PYROLIDINE DERIVATIVES|
    IT1075280B|1977-02-11|1985-04-22|Isf Spa|PROCEDURE FOR THE PREPARATION OF PYROLIDINE DERIVATIVES|
    JPS603387B2|1980-07-10|1985-01-28|Sumitomo Chemical Co|
    DD154225A1|1980-11-10|1982-03-03|Horst Seiferth|METHOD FOR PRODUCING COATED TEXTILE FLUID IMAGES|
    JPS5812272B2|1981-04-28|1983-03-07|Denki Kagaku Kogyo Kk|
    EP0081047B1|1981-12-07|1985-12-18|F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft|Process for the preparation of an optically active lactone, and starting products for the process|
    JPH0345077B2|1982-01-19|1991-07-09|Sumitomo Chemical Co|
    DK43985A|1984-03-09|1985-09-10|Hoffmann La Roche|PROCEDURE FOR PREPARING HETEROCYCLIC COMPOUNDS|
    EP0161580B1|1984-05-18|1990-11-07|F. Hoffmann-La Roche Ag|Process for the preparation of a lacton|
    DE3575717D1|1984-08-25|1990-03-08|Merck Patent Gmbh|METHOD FOR PRODUCING -AND / OR -1,3-DIBENZYL-HEXAHYDRO-1H-FURO IMIDAZOLE-2,4-DION.|
    FI83510C|1985-02-22|1991-07-25|Ciba Geigy Ag|Process for the preparation of novel therapeutically useful bi-2H-pyrroli ndions|
    CH671227A5|1986-12-02|1989-08-15|Lonza Ag|GB8720394D0|1987-08-28|1987-10-07|Ici Plc|Nucleotide probes|
    FI95034C|1989-03-15|1995-12-11|Lonza Ag|Process for the preparation of 1,3-substituted tetrahydro-1H-thieno [3,4-d] imidazol-2-one-4-ylidenepentanoic acid ester|
    DE4107121C1|1991-03-06|1992-06-11|Merck Patent Gmbh, 6100 Darmstadt, De|
    FI935609A|1992-12-18|1994-06-19|Lonza Ag|Asymmetric hydrogenation of dihydrofuroimidazole derivatives|
    HUT71109A|1993-04-20|1995-11-28|Lonza Ag|Process for preparing optical active furoimidazole derivatives by asymmetric hydrogenation|
    CA2122511A1|1993-05-14|1994-11-15|John Mcgarrity|Asymmetric hydrogenation of furoimidazole derivatives|
    DE4411101C2|1994-03-30|1996-02-01|Merck Patent Gmbh|Process for the preparation of a D -- biotin intermediate|
    AU4944397A|1996-10-09|1998-05-05|Lonza A.G.|Method for the manufacture of biotine |
    PT1436322E|2001-10-19|2008-10-23|Isotechnika Inc|Cyclosporine analogue mixtures and their use as immunomodulating agents|
    RU2321593C9|2001-10-19|2008-06-20|Изотехника Инк.|Synthesis of ciclosporin analogues|
    CN103936759B|2014-03-11|2016-01-13|新发药业有限公司|-1,3-dibenzyl-tetrahydrochysene-4H-thieno-[3,4-d] imidazoles-2,4- simple and convenient process for preparing of-diketone|
    CN104530076B|2014-12-17|2016-08-17|新发药业有限公司|-1,3-dibenzyl tetrahydrochysene-4H-thieno [3,4-d] imidazoles-2,4- synthetic method of-diketone|
    CN107686488B|2016-08-05|2020-04-28|浙江医药股份有限公司新昌制药厂|Synthesis method of biotin intermediate|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH5051/86A|CH670644A5|1986-12-18|1986-12-18|LV930120A| LV5265A3|1986-12-18|1993-02-16|Panemiens-1--dihydro-1h-furo--imidazole-2,4-dione|
    LTRP360A| LT2103B|1986-12-18|1993-02-26| -1--dihydro-1H-FURO--imidazole-2,4-DIONE|
    [返回顶部]